Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation.

Macedo C, Walters JT, Orkis EA, Isse K, Elinoff BD, Fedorek SP, McMichael JM, Chalasani G, Randhawa P, Demetris AJ, Zeevi A, Tan H, Shapiro R, Landsittel D, Lakkis FG, Metes D.

Transplantation. 2012 Apr 27;93(8):813-21. doi: 10.1097/TP.0b013e318247a717.

2.

Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.

Kamburova EG, Koenen HJ, van den Hoogen MW, Baas MC, Joosten I, Hilbrands LB.

PLoS One. 2014 Nov 13;9(11):e112658. doi: 10.1371/journal.pone.0112658. eCollection 2014.

3.

Elevation of CD4+ differentiated memory T cells is associated with acute cellular and antibody-mediated rejection after liver transplantation.

Gerlach UA, Vogt K, Schlickeiser S, Meisel C, Streitz M, Kunkel D, Appelt C, Ahrlich S, Lachmann N, Neuhaus P, Pascher A, Sawitzki B.

Transplantation. 2013 Jun 27;95(12):1512-20. doi: 10.1097/TP.0b013e318290de18. Erratum in: Transplantation. 2013 Aug 27;96(4):e33.

PMID:
23619734
4.
5.

Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.

Xu H, Samy KP, Guasch A, Mead SI, Ghali A, Mehta A, Stempora L, Kirk AD.

Am J Transplant. 2016 Feb;16(2):550-64. doi: 10.1111/ajt.13469. Epub 2015 Oct 5.

6.

Kinetics of functionally distinct T-lymphocyte subsets in heart transplant recipients after induction therapy with anti-CD25 monoclonal antibodies.

Lanio N, Sarmiento E, Gallego A, Navarro J, Palomo J, Fernandez-Yañez J, Ruiz M, Fernandez-Cruz E, Carbone J.

Transpl Immunol. 2013 Jun;28(4):176-82. doi: 10.1016/j.trim.2013.04.005. Epub 2013 Apr 20.

PMID:
23611763
7.

Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.

Trzonkowski P, Zilvetti M, Chapman S, Wieckiewicz J, Sutherland A, Friend P, Wood KJ.

Am J Transplant. 2008 Feb;8(2):338-47. doi: 10.1111/j.1600-6143.2007.02078.x.

8.

Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.

Morales J, Bono MR, Fierro A, Iñiguez R, Zehnder C, Rosemblatt M, Calabran L, Herzog C, Benavente D, Aguiló J, Pefaur J, Alba A, Ferrario M, Simon W, Contreras L, Buckel E.

Transplant Proc. 2008 Nov;40(9):3223-8. doi: 10.1016/j.transproceed.2008.03.066.

PMID:
19010240
9.

An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.

Cherukuri A, Salama AD, Carter C, Smalle N, McCurtin R, Hewitt EW, Hernandez-Fuentes M, Clark B, Baker RJ.

Am J Transplant. 2012 Apr;12(4):919-31. doi: 10.1111/j.1600-6143.2011.03891.x. Epub 2012 Mar 5.

10.

Characterization of urinary CD4⁺ and CD8⁺ T cells in kidney transplantation patients with polyomavirus BK infection and allograft rejection.

van Doesum WB, Abdulahad WH, van Dijk MC, Dolff S, van Son WJ, Stegeman CA, Sanders JS.

Transpl Infect Dis. 2014 Oct;16(5):733-43. doi: 10.1111/tid.12273. Epub 2014 Aug 5.

PMID:
25092256
11.

Clinical rejection and persistent immune regulation in kidney transplant patients.

Hendrikx TK, Klepper M, Ijzermans J, Weimar W, Baan CC.

Transpl Immunol. 2009 Jul;21(3):129-35. doi: 10.1016/j.trim.2009.04.003. Epub 2009 May 3.

PMID:
19398001
12.

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.

Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J.

Transplantation. 2005 Aug 27;80(4):457-65.

PMID:
16123718
13.

Terminally differentiated CD8+ Temra cells are associated with the risk for acute kidney allograft rejection.

Betjes MG, Meijers RW, de Wit EA, Weimar W, Litjens NH.

Transplantation. 2012 Jul 15;94(1):63-9. doi: 10.1097/TP.0b013e31825306ff.

PMID:
22691956
14.

The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients.

Sewgobind VD, Kho MM, van der Laan LJ, Hendrikx TK, van Dam T, Tilanus HW, IJzermans JN, Weimar W, Baan CC.

Nephrol Dial Transplant. 2009 May;24(5):1635-44. doi: 10.1093/ndt/gfn778. Epub 2009 Jan 28.

PMID:
19176684
15.

Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.

Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, Chevaile-Ramos JA, Layseca-Espinosa E, González-Amaro R, Portales-Pérez D.

Transpl Immunol. 2009 May;21(1):43-9. doi: 10.1016/j.trim.2009.02.002. Epub 2009 Feb 20.

PMID:
19233271
16.

Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy.

Krystufkova E, Sekerkova A, Striz I, Brabcova I, Girmanova E, Viklicky O.

Nephrol Dial Transplant. 2012 Jun;27(6):2576-82. doi: 10.1093/ndt/gfr693. Epub 2011 Dec 13.

PMID:
22167587
17.

The development of primed/memory CD8+ lymphocytes in vitro and in rejecting kidneys after transplantation.

Akbar AN, Amlot PL, Timms A, Lombardi G, Lechler R, Janossy G.

Clin Exp Immunol. 1990 Aug;81(2):225-31.

18.
19.

Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).

Gallon L, Gagliardini E, Benigni A, Kaufman D, Waheed A, Noris M, Remuzzi G.

Clin J Am Soc Nephrol. 2006 May;1(3):539-45. Epub 2006 Apr 5.

20.

Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?

Lee S, Hammond T, Watson MW, Flexman JP, Cheng W, Fernandez S, Price P.

Clin Exp Immunol. 2010 Jul 1;161(1):118-26. doi: 10.1111/j.1365-2249.2010.04141.x. Epub 2010 Apr 9.

Supplemental Content

Support Center